SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Walker Luke Nathaniel

(Last)

(First)

(Middle)

C/O CASCADIAN THERAPEUTICS, INC.

2601 4TH AVE., SUITE 500

(Street)

SEATTLE

98121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/09/2017

3. Issuer Name and Ticker or Trading Symbol
Cascadian Therapeutics, Inc. [ CASC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Clinical Development

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,990	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	09/30/2019	Common Stock	2,500	$35.88	D
Stock Option (right to buy)	⁽²⁾	12/01/2019	Common Stock	334	$41.52	D
Stock Option (right to buy)	⁽³⁾	12/12/2020	Common Stock	1,250	$28.44	D
Stock Option (right to buy)	⁽⁴⁾	12/12/2021	Common Stock	2,500	$10.44	D
Stock Option (right to buy)	⁽⁵⁾	12/16/2022	Common Stock	1,250	$10.56	D
Stock Option (right to buy)	⁽⁶⁾	09/24/2023	Common Stock	5,834	$21.06	D
Stock Option (right to buy)	⁽⁷⁾	05/17/2024	Common Stock	8,334	$6.9	D
Stock Option (right to buy)	⁽⁸⁾	05/17/2024	Common Stock	20,834	$6.9	D
Stock Option (right to buy)	⁽⁹⁾	01/11/2027	Common Stock	35,100	$4.64	D
Restricted Share Unit (RSU)	⁽¹⁰⁾	01/11/2021	Common Stock	7,800	⁽¹¹⁾	D

Explanation of Responses:

1. The option was 100% vested on September 16, 2015.

2. The option was 100% vested on December 1, 2015.

3. The option was 100% vested on December 12, 2016.

4. The option vests and is exercisable at the rate of 1/4th of the total shares on December 12, 2014 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on December 12, 2017, subject to the holder's continued employment with the issuer on each vesting date.

5. The option vests and is exercisable at the rate of 1/4th of the total shares on December 16, 2015 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on December 16, 2018, subject to the holder's continued employment with the issuer on each vesting date.

6. The option vests and is exercisable at the rate of 1/4th of the total shares on September 24, 2016 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 24, 2019, subject to the holder's continued employment with the issuer on each vesting date.

7. The option vests and is exercisable at the rate of 1/4th of the total shares on May 17, 2017 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on May 17, 2020, subject to the holder's continued employment with the issuer on each vesting date.

8. The option vests and is exercisable at the rate of 1/4th of the total shares on April 1, 2017 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on April 1, 2020, subject to the holder's continued employment with the issuer on each vesting date.

9. The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.

10. Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date.

11. Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs.

Remarks:

	/s/ Julia M. Eastland as attorney-in-fact for Luke N. Walker	03/20/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.